https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.852940/full
Frontiers | Lucanthone Targets Lysosomes to Perturb Glioma Proliferation, Chemoresistance and...
Glioblastoma is the most common and aggressive primary brain tumor in adults. Median survival time remains at 16-20 months despite multimodal treatment with ...
frontierslucanthonetargetslysosomesperturb